NCT01283100View on ClinicalTrials.gov

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2011

Primary Completion Date

March 31, 2011

Study Completion Date

June 30, 2011

Conditions
Infection, Human Immunodeficiency Virus I
Interventions
DRUG

GSK1349572

50mg once every 24 hours for 7 days

DRUG

GSK2248761

200 mg once every 24 hours for 7 days

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY